European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

NEW TECHNOLOGIES FOR AFRICAN SWINE FEVER VACCINES

Descrizione del progetto

Una nuova piattaforma di vaccini per la sicurezza dei suini

La peste suina africana (PSA) minaccia le popolazioni di suini e cinghiali in tutta Europa. La malattia, causata dal virus della PSA (ASFV), pone sfide significative a causa delle sue diverse varianti e della limitata efficacia dei vaccini tradizionali. Le misure attuali faticano a contenere i focolai di PSA, con conseguenti perdite economiche e notevoli preoccupazioni per il benessere degli animali. In questo contesto, il progetto VAX4ASF, finanziato dall’UE, intende fornire una soluzione definitiva, efficace e sicura contro questo virus, altamente contagioso, imprevedibile e complesso. Il progetto cerca di innovare sulla base di precedenti approcci e strategie di vaccinazione con potenziale di successo. Inoltre, introduce nuovi modelli epidemiologici del virus e strategie di controllo, favorendo una migliore comprensione della trasmissione.

Obiettivo

VAX4ASF aims to develop a state-of-the-art platform to produce highly effective and safe vaccines against ASFV targeted for both domestic pigs and wild boars. These vaccine candidates will be designed based on an innovative and robust vaccine platform that will guarantee immune protection against the different circulating ASFV variants in Europe, while avoiding the safety concerns arisen with the use of traditional live attenuated vaccine platforms. Vaccine candidates will effectively induce innate immune response with the adequate adaptive immunity. Moreover, the immunity induced will allow discrimination between vaccinated and infected animals, which will be monitored by complementary DIVA tests developed under the scope of the project. Given the complexity of ASFV genome and the still incomplete knowledge of the mechanisms involved in immune response to ASFV, VAX4ASF aims to further understand the molecular mechanisms of the virus and how it interacts with the host. The developed platform can be used to introduce new mutations based in this new generated knowledge which will allow to improve the efficacy and cross-protection of the vaccine prototypes.
VAX4ASF will provide new virus epidemiology models and control strategies using different mathematical models, leading to a better understanding of the ASFV transmission at the wild-domestic interface. In this way, innovative policies and strategies for ASFV control and management will be generated to ensure an outstanding impact through the continuous involvement of key stakeholders as project partners (farmers, wild board managers, veterinaries, hunters, policy makers...) leading to a profound effect in animal health and worldwide economy. The project relies on a solid collaboration trajectory between leading developers of innovative Animal Health vaccines and the highest experts in ASF field at international level, including partners from Europe, USA, and Kenya for the achievement of this challenge.

Coordinatore

LABORATORIOS HIPRA SA
Contribution nette de l'UE
€ 377 232,50
Indirizzo
AVENIDA DE LA SELVA 135
17170 Amer Girona
Spagna

Mostra sulla mappa

Regione
Este Cataluña Girona
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 1 737 712,50

Partecipanti (15)

Partner (3)